GlaxoSmithKline (GSK) Earns “Hold” Rating from Deutsche Bank

Share on StockTwits

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating restated by equities research analysts at Deutsche Bank in a report released on Thursday. They presently have a GBX 1,525 ($19.67) price target on the stock. Deutsche Bank’s price objective would indicate a potential downside of 1.82% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. Liberum Capital cut GlaxoSmithKline from a “buy” rating to a “hold” rating and boosted their price target for the company from GBX 1,630 ($21.03) to GBX 1,700 ($21.93) in a research report on Thursday, August 30th. Berenberg Bank restated a “buy” rating and issued a GBX 1,790 ($23.09) price target on shares of GlaxoSmithKline in a research report on Thursday, August 23rd. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 1,600 ($20.64) price target on shares of GlaxoSmithKline in a research report on Tuesday, August 21st. Jefferies Financial Group set a GBX 1,775 ($22.90) price target on GlaxoSmithKline and gave the company a “buy” rating in a research report on Thursday, August 16th. Finally, Goldman Sachs Group set a GBX 1,900 ($24.51) price target on GlaxoSmithKline and gave the company a “buy” rating in a research report on Wednesday, August 15th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nine have given a buy rating to the stock. GlaxoSmithKline currently has an average rating of “Hold” and an average target price of GBX 1,546.53 ($19.95).

Shares of GSK stock opened at GBX 1,553.20 ($20.04) on Thursday. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($15.93) and a 52-week high of GBX 1,724.50 ($22.25).

In other GlaxoSmithKline news, insider Philip R. Hampton bought 2,810 shares of the company’s stock in a transaction on Wednesday, July 25th. The shares were bought at an average price of GBX 1,557 ($20.09) per share, for a total transaction of £43,751.70 ($56,439.24). Also, insider David Redfern sold 1,925 shares of the business’s stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.32), for a total value of £30,318.75 ($39,110.87). Insiders have acquired a total of 2,826 shares of company stock worth $4,400,426 in the last quarter.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Earnings Per Share

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply